Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent

A technology of recombinant adenovirus and construct, which is applied in the field of medical genetic engineering, can solve the problems of lack of tumor specificity, limited therapeutic effect, weak efficacy of adenovirus to lyse tumor cells, etc., and achieve the effect of increasing copy number and avoiding attack

Inactive Publication Date: 2004-12-08
WUHAN KDWS BIOLOGICAL TECH CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the second-generation ADV5 gene therapy vectors have some common disadvantages: (1) Although the vectors designed based on the biological basis of adenoviruses have the therapeutic advantage of replicability in tumor conditions, due to various design deficiencies, the obtained adenoviruses are The efficacy of replication and lysis of tumor cells in tumor cells is far weaker than that of wild-type ADV5. For example, the anticancer effective rate of ONYX-015 alone is only 0-14%
(2) The application of the second-generation ADV5 gene therapy vector is still based on local tumor injection, which is greatly limited in application. In most cases, tumor is a systemic disease and needs to be administered intravenously , carry out systemic treatment to control primary and metastatic lesions, therefore, the selectivity of the second-generation ADV5 gene therapy vector and the killing efficiency of tumor cells must be further strengthened to meet the needs of improving drug delivery routes
(3) None of the second-generation ADV5 gene therapy vectors carry effective therapeutic target genes, which limits the therapeutic effect
(4) Since most of the existing molecular targets lack tumor specificity, the strategy of using the second-generation ADV5 gene therapy vector combined with exogenous promoters and therapeutic genes has relative tumor selectivity, but it still cannot avoid Toxic effects of normal tissue cells
[0010] In addition, many tumor molecular drug targets have been identified in recent years. Designing monoclonal antibodies and small molecular compounds against these molecular drug targets has become the main trend in the development of tumor treatment. Some of them have become prescription drugs, and there are still a large number of molecular therapeutic methods It is in the evaluation stage of clinical trials and has achieved good preliminary results
Nevertheless, most of these new molecular targets and their molecular suppression methods lack tumor specificity, and the resulting dose-limiting toxicity is still a key problem that these therapies generally face and urgently need to be solved, which greatly limits the solved the tumor problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent
  • Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent
  • Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Construction of pXC1 series mutant Δ923-931pXC1

[0028] 1. pXC1 was purchased from Microbix Biosystem Inc. (Toronato, Ontario, Canada, catalog number: PD-01-03). The plasmid contains the 21-5790nt sequence of human adenovirus type 5 (ADV5). The plasmid structure is shown in Figure 1 194-358nt of the plasmid is the ADV5 adenovirus packaging signal, the sequence 560-1112nt, 1229-1545nt is the coding sequence of functional protein E1A, 9883-9888nt contains the BamHI restriction site, and 1338-1343nt contains the XbaI restriction site.

[0029] 2. Deletion of 923-931nt by 3 times PCR.

[0030] (1) Acquisition of Fragment 1: Primer 1=5'-CG GGA TCC GGG CCC CCA TTT CC-3' (equivalent to 9883-9902nt; the underlined part is the BamHI restriction site); primer 2 = 5'- GTCACTGGGTGGGATCAC CTC CGG TAC AAG-3' (corresponding to 922-905 nt; the underlined part is complementary to primer 3).

[0031] Use pXC1 as a template for PCR reaction, the total volume of the react...

Embodiment 2

[0036] Example 2: Construction of Δ923-931ADV5 recombinant adenovirus

[0037] 1. pBHGE3 was purchased from Microbix Biosystem Inc. (Toronato, Ontario, Canada, catalog number: PD-01-12). This plasmid contains all genome sequences except the ADV5 packaging signal (194-358nt), and between 194-358nt An artificial sequence is inserted between them, the full length is 37436bp, and its structure is shown in Figure 2.

[0038] When pBHGE3 is obtained from Microbix Biosystem Inc., the total amount is 10 μg. First, electroporate into competent bacteria and pick positive clones. Since the plasmid fragment is very long, CsCl is needed 2 -Eb The plasmid was purified by ultracentrifugation according to the method in the book "Molecular Cloning".

[0039] 2. Homologous recombination method to obtain Δ923-931ADV5 recombinant adenovirus construct, the method is as follows:

[0040] (1) Plant 7.5×10 in a 15cm petri dish 5 293 cells (ATCC, U.S.A, catalog number: CRL-1573), the culture mediu...

Embodiment 3

[0054] Example 3: Construction of the subcloning vector pCDNA3.1-ΔE3 in the ADV5 E3 region

[0055] 1. The full name of the ADV5 E3 region is called the early region 3 of ADV5. Driven by the endogenous promoter, this region encodes 7 proteins. The sequence, structure and function are as follows (see Figure 3): 12.5k, 27858-28179nt, function Unknown; 6.7k, 27547-28736nt, function unknown; gp19k, 28735-29215nt, binds MHC class I antigens, inhibits their presentation to the cell surface, and consequently evades CTL clearance; ADP, 29419-29770nt, lyses cells, releases glands Virus; RIDα, 29784-30057nt, forms a complex with RIDβ, prevents the lysis of TNF, and clears FAS antigen; RIDβ, 30062-30458nt; 14.7k, 30453-30837, inhibits the lysis of TNF.

[0056] The purpose of this experiment is to delete the 28530-29355nt region of the E3 region and insert an exogenous therapeutic gene into the E36.7k / gp 19k region of the recombinant adenovirus.

[0057] 2. Delete 28532-29360nt of ADV5 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to establishment of artificially reformed human adenovirus 5 and use in treatment of cancers by reorganized configuration of adenovirus. It is obtained by extension of fixed-point deficiency, homologous reorganization, transfection, and monoclone purification of adenovirus. Its novelty includes deletion of 9 alkali groups in encoding sequence of ADV 5 gene set E1A conservative sequence 2, deletion of 28532-29360nt of ADV 5 E3 with reversed inserting some of PLK1 cDNA segments. The reorganized configuration of adenovirus can selectively regenerate in tumors, with specific expression of reversed PLK1 cDNA segments to kill tumor cells but normal cells. The configuration is unique effectiveness in diagnosis and treatment of tumors. It provides an ideal therapy of gene target specifility.

Description

1. Technical field [0001] The present invention relates to a construction scheme of human adenovirus type 5 (Human adenovirus type 5, ADV5) recombinant, which is characterized in that: directional deletion of the 923-931nt sequence (CTT ACC TGC of the ADV5 genome, which encodes E1A protein 122 to 124 amino acids), on this basis, the ADV5 E3 region 28532-29360nt was further deleted, and a ClaI restriction site was introduced in the deletion region; an 820bp exogenous PLK1 cDNA fragment was reversely inserted into the ClaI restriction site ( Corresponding to 960-161nt of PLK1 mRNA), so as to obtain the recombinant adenovirus construct Δ923-931ADV5 / ASPLK1 which has a therapeutic effect on tumors. The content of the invention belongs to the technical field of medical genetic engineering. 2. Background technology [0002] Malignant tumors are becoming the primary disease that endangers human health. According to the latest domestic epidemiological survey data, there are more th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61P35/00C12N7/01C12N15/861
Inventor 周剑峰马丁卢运萍王世宣陈刚高庆蕾
Owner WUHAN KDWS BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products